The study comes as Novo Nordisk's Wegovy, Ozempic and similar treatments skyrocket in popularity in the U.S. for causing dramatic weight loss over time.
Last year we invested somewhat heavily in both Novo Nordisk and Ely Lily, who makes Mounjaro, a drug that competes directly with Wegovy. Lily also makes a drug that might be the first to slow the progress of dementias.
If things keep going the way they're going, we can retire in about a year.
This site uses cookies to help personalise content, tailor your experience and to keep you logged in if you register.
By continuing to use this site, you are consenting to our use of cookies.